The challenges because of Covid in India are huge. In some states, there are complete lockdowns and in others, markets and other public places are closed. This makes the news, that the first virtual sale of our mylife YpsoPump insulin pump has taken place in India, even more gratifying.
The new insulin pump user, a 15-year-old girl named Divya, developed diabetes when she was four years old and was previously on MDI therapy (multiple daily injections with an insulin pen). This is now the first time she is using an insulin pump.
Due to the Covid-19 restrictions, the Ypsomed team in India connected with the family virtually via video calls. Using the mylife YpsoPump Explorer app , which can be downloaded free of charge from the Google Play Store and Apple App Store, it was also possible to gather initial impressions. A certified, trained sales partner then visited the family and set up the pump. The rest of the process and the training of the insulin pump took place digitally with the three parties during ten days. The standard procedure for the Ypsomed team is to visit the patient at home or in the doctor's office to demonstrate and discuss the mylife YpsoPump, to answer questions and to build confidence in the system. However, in this case, the team around our Country Manager Sanjay Rajpal was only virtually connected.
This milestone shows us that we are on the right track with our insulin pump and the holistic form of therapy and that we can establish ourselves and help patients even in extraordinary times and difficult markets. We specifically supports customers as well as doctors in India in order to establish insulin pump therapy more in this country, as currently less than 1% of type 1 diabetics are using an insulin pump.